WithdrawnNot Applicable

The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals

United States0Started 2015-06

Plain-language summary

The investigators aim to correlate noninvasive pulmonary artery systolic pressure (PASP) measurements obtained with and without echocardiographic contrast (Optison) during transthoracic echocardiography (TTE) with those obtained invasively and simultaneously during right heart catheterization, as the gold standard.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * consecutive patients (age ≥ 18 years old) undergoing right heart catheterization catheterization laboratory for various clinical indications as part of routine medical care; * only patients with poor acoustic windows will be included (based on previous studies, body habitus); Exclusion Criteria: * atrial fibrillation or other irregular rhythms (bigeminy, frequent ectopy) * pregnant women * known allergy to perflutren, blood products, albumin * patients who cannot receive blood products due to religious beliefs * evidence of intracardiac right to left shunting

What they're measuring

Noninvasively derived PASP values in patients with versus without Optison enhanced TR continuous wave (CW) spectral Doppler envelopes in patients with technically inadequate studies to PASP measurements obtained invasively and simultaneously

Timeframe: up to 6 months

Trial details

NCT IDNCT02560116

SponsorNorthwell Health

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2015-12

View on ClinicalTrials.gov More Hypertension, Pulmonary trials